Senti Biosciences Q1 2025 Earnings Report

Senti Biosciences EPS Results

• Actual EPS: -$1.41
• Consensus EPS: -$0.56
• Beat/Miss: Missed by -$0.85
• One Year Ago EPS: N/A

Senti Biosciences Revenue Results

• Actual Revenue: $1.30 million
• Expected Revenue: $1.30 million
• Beat/Miss: Met Expectations
• YoY Revenue Growth: N/A

Senti Biosciences Announcement Details

• Quarter: Q1 2025
• Date: 5/6/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 6, 2025
• Conference Call Time: 4:00PM ET

Senti Biosciences (NASDAQ:SNTI) (NASDAQ: SNTI) is a clinical‐stage biotechnology company focused on developing programmable cell and gene therapies through its proprietary synthetic biology platform. The company engineers living cells with precise genetic circuits designed to detect and respond to disease signals in real time. Senti’s modular Gene Circuits Platform integrates sensors, controllers and effectors to create therapies that sense disease environments and orchestrate controlled therapeutic responses.

Leveraging its technology, Senti is advancing a pipeline of engineered cell therapy candidates targeting oncology and other serious diseases. The company’s programs include allogeneic and autologous cell therapies equipped with safety switches and logic gating to enhance specificity and reduce off‐target effects. In addition to cell therapy, Senti is exploring in vivo gene circuit applications for chronic diseases, applying its design principles to deliver genes that activate only under predefined physiological conditions.

Founded in 2017 and headquartered in South San Francisco, Senti Biosciences grew out of pioneering work in synthetic biology at leading academic institutions. Since its inception, the company has entered strategic collaborations with major pharmaceutical partners to expand its research capabilities and accelerate clinical development. Senti operates research and manufacturing facilities in the San Francisco Bay Area, with plans to broaden its footprint as it progresses toward regulatory filings.

Senti Biosciences is led by President and Chief Executive Officer David Cannistra, who brings extensive experience in biotechnology growth and commercialization. Co‐founder Tim Lu, Ph.D., serves as Executive Chairman and drives the scientific vision, drawing on his background in synthetic biology and gene editing. The leadership team is complemented by seasoned experts in clinical development, regulatory affairs and manufacturing, positioning Senti to advance its next-generation therapies toward the clinic.